- Home
- GRNT vs CDNA Comparison
GRNT vs CDNA Comparison
Compare GRNT & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRNT
- CDNA
- Stock Information
- Founded
- GRNT 2013
- CDNA 1998
- Country
- GRNT United States
- CDNA United States
- Employees
- GRNT N/A
- CDNA N/A
- Industry
- GRNT Blank Checks
- CDNA Medical Specialities
- Sector
- GRNT Finance
- CDNA Health Care
- Exchange
- GRNT Nasdaq
- CDNA Nasdaq
- Market Cap
- GRNT 793.2M
- CDNA 712.2M
- IPO Year
- GRNT N/A
- CDNA 2014
- Fundamental
- Price
- GRNT $5.73
- CDNA $12.97
- Analyst Decision
- GRNT Buy
- CDNA Buy
- Analyst Count
- GRNT 2
- CDNA 6
- Target Price
- GRNT $7.50
- CDNA $27.67
- AVG Volume (30 Days)
- GRNT 600.1K
- CDNA 1.3M
- Earning Date
- GRNT 08-07-2025
- CDNA 08-06-2025
- Dividend Yield
- GRNT 7.68%
- CDNA N/A
- EPS Growth
- GRNT N/A
- CDNA N/A
- EPS
- GRNT 0.25
- CDNA 1.00
- Revenue
- GRNT $409,332,000.00
- CDNA $340,826,000.00
- Revenue This Year
- GRNT $32.19
- CDNA $12.81
- Revenue Next Year
- GRNT $14.74
- CDNA $13.36
- P/E Ratio
- GRNT $23.30
- CDNA $12.99
- Revenue Growth
- GRNT 10.32
- CDNA 14.72
- 52 Week Low
- GRNT $4.52
- CDNA $10.96
- 52 Week High
- GRNT $7.00
- CDNA $33.21
- Technical
- Relative Strength Index (RSI)
- GRNT 62.42
- CDNA 47.53
- Support Level
- GRNT $5.17
- CDNA $11.27
- Resistance Level
- GRNT $5.53
- CDNA $12.14
- Average True Range (ATR)
- GRNT 0.20
- CDNA 0.69
- MACD
- GRNT 0.08
- CDNA 0.28
- Stochastic Oscillator
- GRNT 96.52
- CDNA 84.66
About GRNT Granite Ridge Resources Inc.
Granite Ridge Resources Inc is a scaled, non-operated oil and gas exploration and production company. It invests in a diversified portfolio of production and top-tier acreage across the Permian and other prolific U.S. basins in partnership with operators. It generates maximum revenue from Oil.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.